InVivo Therapeutics Names Veteran Biomaterials Expert Bill D'Agostino as Senior Director of Manufacturing & Engineering

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and neurotrauma, today announced the appointment of Bill D'Agostino as Senior Director of Manufacturing & Engineering.

An executive leader focused on rapid market growth, Mr. D'Agostino joins InVivo following fifteen years at Covidien and, most recently, seven years at Angiotech Pharmaceuticals as Vice President, Engineering. In his career to date, Mr. DAgostino has launched more than 100 new polymer products including families of biodegradable sutures.

Mr. D'Agostino is a seasoned professional in medical devices and pharmaceutical excelling in all aspects of Research & Development, Engineering, GMP Operations and Quality Assurance, and has a wealth of expertise on technologies such as hydrogels and biodegradable sutures. He has worked on every stage of the product life cycle including end-user requirements, risk management, feasibility, development, quality systems, design verification, pilot manufacturing, validations, regulatory approvals, clinical field testing, full manufacturing, product launch, marketing and post-market surveillance.

Said InVivo CEO Frank Reynolds, Bill has a unique history and expertise in getting products to market. I am confident that his wide-ranging experience with all aspects of commercializing medical devices and with FDA submissions will play a pivotal role as we plan to begin a clinical trial for First in Man use of biopolymer scaffolding to treat acute SCI.

There is no time like the present for driving innovation to a higher level, and InVivo Therapeutics is just the company to do it considering the multiple products in our pipeline and the significant unmet medical needs in neurotrauma, said Mr. DAgostino.

Mr. D'Agostino is a licensed Professional Engineer (PE), with a Bachelor of Science degree in Chemical Engineering & Materials Engineering from the University of Connecticut. He received his MBA with the highest honors from the University of Dallas.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed from traumatic spinal cord injuries. The company was founded in 2005 based on proprietary technology co-invented by Robert S. Langer, ScD. Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital. In 2011, the company earned the prestigious 2011 David F. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, MA. For more details, visit http://www.invivotherapeutics.com.

Safe Harbor Statement

Original post:
InVivo Therapeutics Names Veteran Biomaterials Expert Bill D'Agostino as Senior Director of Manufacturing & Engineering